Clinical Efficacy of Radiotherapy Combined with Targeted Therapy in Ad-vanced Patients with Non-small Cell Lung Cancer
Objective To investigate the clinical efficacy of radiotherapy combined with targeted therapy in advanced non-small cell lung cancer(NSCLC)patients.Methods A total of 96 patients with advanced non-small cell lung can-cer treated in the Central Hospital of Zibo City at Shandong Province from June 2022 to June 2023 were conveniently selected as the study objects,and they were divided into control group and observation group by random number table method,with 48 cases in each group.The control group received radiotherapy,and the observation group received ra-diotherapy combined with targeted therapy.The efficacy,tumor markers,immune function and incidence of adverse re-actions were compared between the two groups.Results The remission rate(56.25%)and disease control rate(87.50%)in the observation group were higher than those in the control group(35.42%,68.75%),and the differences were statistically significant(χ2=4.196,4.937,both P<0.05).After treatment,the levels of keratin 19 fragment,car-cinoembryonic antigen,carbohydrate antigen 199 and CD8+ in observation group were lower than those in control group,and the levels of CD4+ and CD3+ were higher than those in control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Radiotherapy combined with targeted therapy has a high therapeutic effect on ad-vanced non-small cell lung cancer patients,and can obtain a higher control rate.It can effectively down-regulate the levels of cytokeratin 19 fragment,carcinoembryonic antigen and carbohydrate antigen 199,and regulate immunity without increasing adverse reactions.
NETL
NSTL
万方数据
维普
